135 related articles for article (PubMed ID: 28439844)
1. Therapeutic efficacy of α-radioimmunotherapy with different activity levels of the
Gustafsson-Lutz A; Bäck T; Aneheim E; Hultborn R; Palm S; Jacobsson L; Morgenstern A; Bruchertseifer F; Albertsson P; Lindegren S
EJNMMI Res; 2017 Dec; 7(1):38. PubMed ID: 28439844
[TBL] [Abstract][Full Text] [Related]
2. Comparison of therapeutic efficacy and biodistribution of 213Bi- and 211At-labeled monoclonal antibody MX35 in an ovarian cancer model.
Gustafsson AM; Bäck T; Elgqvist J; Jacobsson L; Hultborn R; Albertsson P; Morgenstern A; Bruchertseifer F; Jensen H; Lindegren S
Nucl Med Biol; 2012 Jan; 39(1):15-22. PubMed ID: 21958859
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic efficacy and tumor dose estimations in radioimmunotherapy of intraperitoneally growing OVCAR-3 cells in nude mice with (211)At-labeled monoclonal antibody MX35.
Elgqvist J; Andersson H; Bäck T; Hultborn R; Jensen H; Karlsson B; Lindegren S; Palm S; Warnhammar E; Jacobsson L
J Nucl Med; 2005 Nov; 46(11):1907-15. PubMed ID: 16269606
[TBL] [Abstract][Full Text] [Related]
4. Fractionated radioimmunotherapy of intraperitoneally growing ovarian cancer in nude mice with 211At-MX35 F(ab')2: therapeutic efficacy and myelotoxicity.
Elgqvist J; Andersson H; Bäck T; Claesson I; Hultborn R; Jensen H; Lindegren S; Olsson M; Palm S; Warnhammar E; Jacobsson L
Nucl Med Biol; 2006 Nov; 33(8):1065-72. PubMed ID: 17127181
[TBL] [Abstract][Full Text] [Related]
5. Administered activity and metastatic cure probability during radioimmunotherapy of ovarian cancer in nude mice with 211At-MX35 F(ab')2.
Elgqvist J; Andersson H; Bernhardt P; Bäck T; Claesson I; Hultborn R; Jensen H; Johansson BR; Lindegren S; Olsson M; Palm S; Warnhammar E; Jacobsson L
Int J Radiat Oncol Biol Phys; 2006 Nov; 66(4):1228-37. PubMed ID: 17145538
[TBL] [Abstract][Full Text] [Related]
6. Repeated Intraperitoneal alpha-Radioimmunotherapy of Ovarian Cancer in Mice.
Elgqvist J; Andersson H; Jensen H; Kahu H; Lindegren S; Warnhammar E; Hultborn R
J Oncol; 2010; 2010():394913. PubMed ID: 19859581
[TBL] [Abstract][Full Text] [Related]
7. Comparison of 211At-PRIT and 211At-RIT of ovarian microtumors in a nude mouse model.
Frost SH; Bäck T; Chouin N; Hultborn R; Jacobsson L; Elgqvist J; Jensen H; Albertsson P; Lindegren S
Cancer Biother Radiopharm; 2013 Mar; 28(2):108-14. PubMed ID: 23230896
[TBL] [Abstract][Full Text] [Related]
8. Cure of Human Ovarian Carcinoma Solid Xenografts by Fractionated α-Radioimmunotherapy with
Bäck T; Chouin N; Lindegren S; Kahu H; Jensen H; Albertsson P; Palm S
J Nucl Med; 2017 Apr; 58(4):598-604. PubMed ID: 27688477
[TBL] [Abstract][Full Text] [Related]
9. Intraperitoneal alpha-particle radioimmunotherapy of ovarian cancer patients: pharmacokinetics and dosimetry of (211)At-MX35 F(ab')2--a phase I study.
Andersson H; Cederkrantz E; Bäck T; Divgi C; Elgqvist J; Himmelman J; Horvath G; Jacobsson L; Jensen H; Lindegren S; Palm S; Hultborn R
J Nucl Med; 2009 Jul; 50(7):1153-60. PubMed ID: 19525452
[TBL] [Abstract][Full Text] [Related]
10. Intraperitoneal alpha-radioimmunotherapy in mice using different specific activities.
Elgqvist J; Andersson H; Haglund E; Jensen H; Kahu H; Lindegren S; Warnhammar E; Hultborn R
Cancer Biother Radiopharm; 2009 Aug; 24(4):509-13. PubMed ID: 19694586
[TBL] [Abstract][Full Text] [Related]
11. Alpha-radioimmunotherapy of intraperitoneally growing OVCAR-3 tumors of variable dimensions: Outcome related to measured tumor size and mean absorbed dose.
Elgqvist J; Andersson H; Bäck T; Claesson I; Hultborn R; Jensen H; Johansson BR; Lindegren S; Olsson M; Palm S; Warnhammar E; Jacobsson L
J Nucl Med; 2006 Aug; 47(8):1342-50. PubMed ID: 16883015
[TBL] [Abstract][Full Text] [Related]
12. In vivo distribution of avidin-conjugated MX35 and (211)At-labeled, biotinylated poly-L-lysine for pretargeted intraperitoneal α-radioimmunotherapy.
Frost SH; Bäck T; Chouin N; Jensen H; Hultborn R; Jacobsson L; Lindegren S
Cancer Biother Radiopharm; 2011 Dec; 26(6):727-36. PubMed ID: 22087606
[TBL] [Abstract][Full Text] [Related]
13. Locoregional alpha-radioimmunotherapy of intraperitoneal tumor cell dissemination using a tumor-specific monoclonal antibody.
Huber R; Seidl C; Schmid E; Seidenschwang S; Becker KF; Schuhmacher C; Apostolidis C; Nikula T; Kremmer E; Schwaiger M; Senekowitsch-Schmidtke R
Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3922S-8S. PubMed ID: 14506190
[TBL] [Abstract][Full Text] [Related]
14. α- Versus β-Emitting Radionuclides for Pretargeted Radioimmunotherapy of Carcinoembryonic Antigen-Expressing Human Colon Cancer Xenografts.
Heskamp S; Hernandez R; Molkenboer-Kuenen JDM; Essler M; Bruchertseifer F; Morgenstern A; Steenbergen EJ; Cai W; Seidl C; McBride WJ; Goldenberg DM; Boerman OC
J Nucl Med; 2017 Jun; 58(6):926-933. PubMed ID: 28232604
[TBL] [Abstract][Full Text] [Related]
15. 211At radioimmunotherapy of subcutaneous human ovarian cancer xenografts: evaluation of relative biologic effectiveness of an alpha-emitter in vivo.
Bäck T; Andersson H; Divgi CR; Hultborn R; Jensen H; Lindegren S; Palm S; Jacobsson L
J Nucl Med; 2005 Dec; 46(12):2061-7. PubMed ID: 16330571
[TBL] [Abstract][Full Text] [Related]
16. Intraperitoneal Alpha-Radioimmunotherapy of Advanced Ovarian Cancer in Nude Mice Using Different High Specific Activities.
Elgqvist J; Ahlberg D; Andersson H; Jensen H; Johansson BR; Kahu H; Olsson M; Lindegren S
World J Oncol; 2010 Jun; 1(3):101-110. PubMed ID: 29147189
[TBL] [Abstract][Full Text] [Related]
17. Intravesical alpha-radioimmunotherapy with 213Bi-anti-EGFR-mAb defeats human bladder carcinoma in xenografted nude mice.
Pfost B; Seidl C; Autenrieth M; Saur D; Bruchertseifer F; Morgenstern A; Schwaiger M; Senekowitsch-Schmidtke R
J Nucl Med; 2009 Oct; 50(10):1700-8. PubMed ID: 19793735
[TBL] [Abstract][Full Text] [Related]
18. Fractionated intravesical radioimmunotherapy with (213)Bi-anti-EGFR-MAb is effective without toxic side-effects in a nude mouse model of advanced human bladder carcinoma.
Fazel J; Rötzer S; Seidl C; Feuerecker B; Autenrieth M; Weirich G; Bruchertseifer F; Morgenstern A; Senekowitsch-Schmidtke R
Cancer Biol Ther; 2015; 16(10):1526-34. PubMed ID: 26177233
[TBL] [Abstract][Full Text] [Related]
19. Pretargeted alpha emitting radioimmunotherapy using (213)Bi 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid-biotin.
Yao Z; Zhang M; Garmestani K; Axworthy DB; Mallett RW; Fritzberg AR; Theodore LJ; Plascjak PS; Eckelman WC; Waldmann TA; Pastan I; Paik CH; Brechbiel MW; Carrasquillo JA
Clin Cancer Res; 2004 May; 10(9):3137-46. PubMed ID: 15131055
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]